Exicure, Inc.

XCUR Healthcare Biotechnology

Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022. In the quarter to June 2026, EPS grew 56.1% and free cash flow grew 65.4%, each against the same quarter a year earlier.

1.11 0.01 −0.89%
Market cap
$7.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
n/a
Altman Z
−18.31
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
0.56 0.79 1.19 1.96
Net Debt/EBITDA
1.69 1.70 1.78 1.90
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.18) (0.15) (0.54)
Book value per Share
0.15 0.33 0.62 1.10
Free Cash Flow
(0.89) (1.14) (0.93) (3.42)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates